File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

postgraduate thesis: Adducin 3 and temozolomide resistance in glioblastoma multiforme

TitleAdducin 3 and temozolomide resistance in glioblastoma multiforme
Authors
Issue Date2012
PublisherThe University of Hong Kong (Pokfulam, Hong Kong)
Citation
Zhuang, T. [莊天放]. (2012). Adducin 3 and temozolomide resistance in glioblastoma multiforme. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833509
AbstractGlioblastoma multiforme (GBM), a grade IV malignant astrocytic tumor according to WHO classification, is one of the most common and malignant brain tumor. Temozolomide (TMZ) is the current standard treatment for GBM. Nevertheless, resistance to chemotherapy in GBM is common and therefore a major obstacle to successful treatment. Adducin 3 (ADD3), a cytoskeletal protein, has been found to be associated with chemoresistance in osteosarcoma, but its potential role in glioblastoma is unclear. A TMZ-resistant model was established by chronically exposing the glioma cells (D54 cell line) to an increasing dose of TMZ. A resistant subclone (D54-R) was successfully generated. ADD3 expression level was found to be upregulated in the D54-R when compared to the parental D54 cells (D54-C). CD133 is a putative cancer stem cell marker. Its expression level was found also to be higher in D54-R when compared to D54-C cells. Among the D54-R cells, a subgroup of cells was found to express ADD3 intensely. The proportion of these spherical cells was higher in D54-R than D54-C. Moreover, these cells were spherical in morphology and expressed putative cancer stem cell markers: CD133, NANOG and OCT-3/-4. Therefore, ADD3 is associated with cancer stem cells in human glioma. The upregulation of ADD3 expression is associated with TMZ-resistance in GBM.
DegreeMaster of Research in Medicine
SubjectGlioblastoma multiforme - Chemotherapy.
Drug resistance in cancer cells.
Cytoskeletal proteins.
Dept/ProgramSurgery

 

DC FieldValueLanguage
dc.contributor.authorZhuang, Tin-fong.-
dc.contributor.author莊天放.-
dc.date.issued2012-
dc.identifier.citationZhuang, T. [莊天放]. (2012). Adducin 3 and temozolomide resistance in glioblastoma multiforme. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833509-
dc.description.abstractGlioblastoma multiforme (GBM), a grade IV malignant astrocytic tumor according to WHO classification, is one of the most common and malignant brain tumor. Temozolomide (TMZ) is the current standard treatment for GBM. Nevertheless, resistance to chemotherapy in GBM is common and therefore a major obstacle to successful treatment. Adducin 3 (ADD3), a cytoskeletal protein, has been found to be associated with chemoresistance in osteosarcoma, but its potential role in glioblastoma is unclear. A TMZ-resistant model was established by chronically exposing the glioma cells (D54 cell line) to an increasing dose of TMZ. A resistant subclone (D54-R) was successfully generated. ADD3 expression level was found to be upregulated in the D54-R when compared to the parental D54 cells (D54-C). CD133 is a putative cancer stem cell marker. Its expression level was found also to be higher in D54-R when compared to D54-C cells. Among the D54-R cells, a subgroup of cells was found to express ADD3 intensely. The proportion of these spherical cells was higher in D54-R than D54-C. Moreover, these cells were spherical in morphology and expressed putative cancer stem cell markers: CD133, NANOG and OCT-3/-4. Therefore, ADD3 is associated with cancer stem cells in human glioma. The upregulation of ADD3 expression is associated with TMZ-resistance in GBM.-
dc.languageeng-
dc.publisherThe University of Hong Kong (Pokfulam, Hong Kong)-
dc.relation.ispartofHKU Theses Online (HKUTO)-
dc.rightsThe author retains all proprietary rights, (such as patent rights) and the right to use in future works.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.source.urihttp://hub.hku.hk/bib/B48335095-
dc.subject.lcshGlioblastoma multiforme - Chemotherapy.-
dc.subject.lcshDrug resistance in cancer cells.-
dc.subject.lcshCytoskeletal proteins.-
dc.titleAdducin 3 and temozolomide resistance in glioblastoma multiforme-
dc.typePG_Thesis-
dc.identifier.hkulb4833509-
dc.description.thesisnameMaster of Research in Medicine-
dc.description.thesislevelMaster-
dc.description.thesisdisciplineSurgery-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5353/th_b4833509-
dc.date.hkucongregation2012-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats